Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25 1월 2024 - 9:00PM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that Diana Hausman,
M.D., a member of Zentalis’ Board of Directors, was appointed as
Chief Medical Officer, and Kyle Rasbach, Ph.D., Pharm.D., was
appointed as Chief Business Officer.
“We are pleased to welcome Diana and Kyle to our management
team. Diana brings deep oncology development experience and a
detailed understanding of the azenosertib clinical plans as a
result of her service on our Board of Directors. Diana is ideally
suited to help us execute on our clinical development strategy for
our potentially transformative WEE1 inhibitor, azenosertib, which
remains on track across multiple ongoing studies,” said Kimberly
Blackwell, M.D., Chief Executive Officer of Zentalis. “Kyle comes
to us from Eventide Asset Management, where he co-managed their
Healthcare and Life Sciences Fund and developed an understanding of
the Company and the potential of azenosertib in ovarian cancer and
other tumors. We believe Kyle’s experience as a biotechnology
portfolio manager, with a background in scientific research, will
help us drive the Company’s growth and value creation.”
Dr. Hausman is an oncologist with extensive experience in all
aspects of drug development and clinical strategy. She has over a
decade of experience as a Chief Medical Officer, having previously
served in the role at Link Immunotherapeutics, Lengo Therapeutics,
Zymeworks, and Oncothyreon. During her career, she has contributed
to the development of multiple cancer therapeutics, including small
molecules, antibody drug conjugates, and immunotherapies. Her
experience includes overseeing trials from first-in-human/Phase 1
to Phase 3. Dr. Hausman currently serves on the Board of Directors
of Immuneering. In connection with her appointment as Chief Medical
Officer, Dr. Hausman resigned from Zentalis’ Board of Directors.
Dr. Hausman holds an M.D. from the University of Pennsylvania
School of Medicine, and an A.B. in biology from Princeton
University.
Dr. Hausman will succeed Carrie Brownstein, M.D., who is
stepping down for personal reasons. Dr. Brownstein will remain with
Zentalis as a consultant for a transitional period. “Carrie built
an incredibly talented team during her time with us. I would like
to thank Carrie for her leadership and contributions to advancing
azenosertib in the clinic,” stated Dr. Blackwell.
Dr. Rasbach comes to Zentalis from Eventide Asset Management,
where he was a Portfolio Manager for Eventide’s healthcare and life
sciences strategies, a Managing Director for Eventide Ventures, and
a Senior Research Analyst for other Eventide investments. Dr.
Rasbach has extensive experience in clinical pharmacology, basic
science, and healthcare equity research. Prior to joining Eventide,
Dr. Rasbach was a Managing Partner at Pappas Capital, an equity
research analyst and Vice President at T. Rowe Price, and an equity
research associate and Vice President at Cowen and Company. Dr.
Rasbach holds a Ph.D. in Pharmaceutical and Biomedical Sciences as
well as a Pharm.D. from the Medical University of South Carolina,
an M.B.A. from The Citadel, and a B.S. from Denison University.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers. The Company’s lead product
candidate, azenosertib (ZN-c3), is a potentially first-in-class and
best-in-class WEE1 inhibitor for advanced solid tumors and
hematologic malignancies. Azenosertib is being evaluated as a
monotherapy and in combination across multiple clinical trials and
has broad franchise potential. In clinical trials, azenosertib has
been well tolerated and has demonstrated anti-tumor activity as a
single agent across multiple tumor types and in combination with
several chemotherapy backbones. As part of its azenosertib clinical
development program, the Company is exploring enrichment strategies
targeting tumors of high genomic instability, such as Cyclin E1
positive tumors and homologous recombination deficient tumors. The
Company is also leveraging its extensive experience and
capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including statements regarding the
anticipated contribution and value of new management team members;
the potential for azenosertib to be transformative; our plans to
drive the Company’s growth and value creation; the potential of
azenosertib in ovarian cancer and other tumors; our plans to
execute on our clinical development strategy for azenosertib; the
potential for azenosertib to be first-in-class and best-in-class;
the broad franchise potential of azenosertib; our plans to explore
enrichment strategies targeting tumors of high genomic instability;
and our plans to advance our research on protein degraders. The
terms “advance,” “believe,” “drive,” “is,” “potentially,” “will,”
and similar references are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties, and
other important factors that may cause our actual results,
performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied
by the forward-looking statements, including, but not limited to,
the following: our limited operating history, which may make it
difficult to evaluate our current business and predict our future
success and viability; we have and expect to continue to incur
significant losses; our need for additional funding, which may not
be available; our plans, including the costs thereof, of
development of any diagnostic tools, if needed; the outcome of
preclinical testing and early trials may not be predictive of the
success of later clinical trials; failure to identify additional
product candidates and develop or commercialize marketable
products; potential unforeseen events during clinical trials could
cause delays or other adverse consequences; risks relating to the
regulatory approval process or ongoing regulatory obligations;
failure to obtain U.S. or international marketing approval; our
product candidates may cause serious adverse side effects;
inability to maintain our collaborations, or the failure of these
collaborations; our reliance on third parties; effects of
significant competition; the possibility of system failures or
security breaches; risks relating to intellectual property; our
ability to attract, retain and motivate qualified personnel, and
risks relating to management transitions; significant costs as a
result of operating as a public company; and the other important
factors discussed under the caption “Risk Factors” in our most
recently filed periodic report on Form 10-K or 10-Q and subsequent
filings with the U.S. Securities and Exchange Commission (SEC) and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
ZENTALIS® and its associated logos are trademarks of
Zentalis and/or its affiliates. All website addresses and other
links in this press release are for information only and are not
intended to be an active link or to incorporate any website or
other information into this press release.
Contact
Carlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024